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priately selected young patients. Resurfacing implants demand
high manufacturing standards to produce consistently low wear
bearings. The background research and better understanding of
implant failure would suggest that hip resurfacing technology has
now developed beyond that of an experimental procedure. Only
long term results and experience with this technology in the wider
Orthopaedic community will give the answer as to whether the
results will be durable, or if hip resurfacing will simply become a
bone conserving intervention prior to conventional THR.
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MINIMAL INVASIVE HIP SURGERY: FICTION OR
REALITY?
Guenther Klaus
Developmental dysplasia of the hip, femoroacetabular impinge-
ment and advanced hip osteoarthritis are common disorders.
Numerous studies reinforce the improved pain and function after
conventional joint preserving treatment and/or joint replacement
surgery for these conditions.
With the introduction of innovative surgical techniques and instru-
ments new approaches have been developed, however, in order
to decrease morbidity and length of hospital stay. Arthroscopic
treatment of hip osteoarthritis, "minimal-invasive" hip replace-
ment and less invasive procedures in dysplasia or impingement
surgery are already of practical relevance.
Aim of the presentation is to inform about recent surgical de-
velopments and to discuss critically the potential advantages as
well as disadvantages of these new approaches.
In an increasing number of observational studies as well as
randomized trials the effects of minimal invasive techniques are
currently investigated. The clinical data base is not yet sufficient
to allow definite technology assessment, but – based on current
literature review as well as own experiences – first conclusions
can be drawn. Most articles, who have been published about less
invasive hip replacement, do not have a scientific quality high
enough to prove a substantial benefit. Few studies with an ap-
propriate level of evidence agree on reduced early postoperative
morbidity and improved function of patients after less invasive
surgical approaches, but complication rates and implant position
must be viewed with caution. There seems to be also a large
influence by the surgeon’s experience.
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REGULATORY ASPECTS OF IMPLEMENTING IMAGING
BIOMARKERS
Brad Wyman
Purpose: Many biomarkers extracted from imaging data have
been proposed and may potentially have an impact on the suc-
cessful development of disease modifying osteoarthritis drugs
(DMOAD) or as use as diagnostic tools. However, often the
focus of biomarker development, which usually originates in aca-
demic centers or small companies, is on the technology with
less consideration given to the regulatory aspects of implemen-
tation. This presentation will cover the regulatory issues required
for successful implementation of imaging biomarkers including
patient confidentiality protection, Good Clinical Practice (GCP),
Part 11 compliance, with an emphasis on design controls.
Description: The regulatory requirements for biomarkers will
be dependent on the use as a diagnostic or the trial specifica-
tions. An early phase DMOAD trial for internal decision making
has fewer requirements while a biomarker implemented as a
diagnostic device would have more stringent requirements.
The requirements protecting patient confidentiality vary in detail
between countries but in general prevent disclosing information,
such as name, that could readily identify the subject. This re-
quirement is universal for any clinical trial. Also, the principles of
GCP are expected to be followed by any phase of trial with more
scrutiny being required for registration trials.
Implementation of design controls is required for US and Eu-
ropean approval of any medical device. While implementation
of design controls is probably not required for biomarkers used
in DMOAD trials, the concepts, when properly implemented,
facilitates improved quality and operational success.
Since most of the imaging biomarkers have a significant soft-
ware component, the implementation of design controls will be
discussed in the context of software development. The most
common departure from proper software design is beginning the
process with coding. However, the key element to successful
software implementation is advanced planning prior to coding.
The first step is to establish a Quality System that defines the
processes for implementation at each phase. The next step is to
define and rigorously document the requirements in a software
requirements specification. Next are the detailed design of the
system including both the high-level architecture and the detailed
software component design. This is followed by implementation
or coding in conjunction with execution of a well documented
verification and validation plan. This systematically tests from
module level through system’s level. Each of these steps requires
proper documentation, review and traceability analysis to ensure
quality.
In the USA, studies that require handling of electronic records,
such as images, or involve computer systems invoke CFR Title
21 Part 11. The key aspects of this regulation are maintaining the
integrity and security of the data. This has greater implication for
registration trials, though the security is required for maintaining
subject confidentiality.
Conclusions: Attention to the regulatory requirements is critical
to the successful implementation of imaging biomarkers in either
DMOAD trials or as diagnostics. Developing biomarker tools with
design controls can help to ensure quality which is valuable even
if not strictly required by regulatory agencies.
